Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Bullish option flow detected in CVS Health (CVS) with 33,211 calls trading, 1.7x expected, and implied vol increasing over 7 points to 47.44%.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $241,558, and 4 are calls, for a total ...

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and ...

CVS Health CVS shareholders are experiencing a rough period as the stock continues to face significant downward pressure. Recent reports about the company's strategic restructuring plans have ...

Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on CVS Health (CVS – Research Report) today and set a price target of ...

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...

CVS Health Corp. shares dipped below $50 on Thursday ... Separately, PBMs are being sued by the Federal Trade Commission. The industry is pushing back, saying the lawsuits are without merit ...

Innovative approach uses a transparent formula built on the drug acquisition cost, a set markup, and a fee to reflect the quality of pharmacy services provided New reimbursement model supports ...

In September, the Federal Trade Commission sued the PBMs owned by CVS, UnitedHealth and Cigna, alleging they artificially raised prices on insulin drugs. CVS is a PBM through its CVS Caremark ...